Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Histopathologic variables differentially affect melanoma survival by age at diagnosis.

Mishra K, Barnhill RL, Paddock LE, Fine JA, Berwick M.

Pigment Cell Melanoma Res. 2019 Jul;32(4):593-600. doi: 10.1111/pcmr.12770. Epub 2019 Feb 16.

PMID:
30706692
2.

Sun exposure and mortality from melanoma.

Berwick M, Armstrong BK, Ben-Porat L, Fine J, Kricker A, Eberle C, Barnhill R.

J Natl Cancer Inst. 2005 Feb 2;97(3):195-9.

PMID:
15687362
3.

Predicting five-year outcome for patients with cutaneous melanoma in a population-based study.

Barnhill RL, Fine JA, Roush GC, Berwick M.

Cancer. 1996 Aug 1;78(3):427-32. Erratum in: Cancer 1997 Jan 15;79(2):423.

PMID:
8697387
4.

Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: a population-based study.

Thomas NE, Kricker A, Waxweiler WT, Dillon PM, Busman KJ, From L, Groben PA, Armstrong BK, Anton-Culver H, Gruber SB, Marrett LD, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Venn A, Kanetsky PA, Orlow I, Paine S, Ollila DW, Reiner AS, Luo L, Hao H, Frank JS, Begg CB, Berwick M; Genes, Environment, and Melanoma (GEM) Study Group.

JAMA Dermatol. 2014 Dec;150(12):1306-314.

5.

Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.

Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS.

J Clin Oncol. 2007 Mar 1;25(7):869-75.

PMID:
17327608
6.

Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.

Thomas NE, Edmiston SN, Alexander A, Groben PA, Parrish E, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, From L, Busam KJ, Hao H, Orlow I, Kanetsky PA, Luo L, Reiner AS, Paine S, Frank JS, Bramson JI, Marrett LD, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Cust AE, Ollila DW, Begg CB, Berwick M, Conway K; GEM Study Group.

JAMA Oncol. 2015 Jun;1(3):359-68. Erratum in: JAMA Oncol. 2015 Jun;1(3):285.

7.

Telomerase reverse transcriptase promoter mutations and solar elastosis in cutaneous melanoma.

Lade-Keller J, Yuusufi S, Riber-Hansen R, Steiniche T, Stougaard M.

Melanoma Res. 2018 Oct;28(5):398-409. doi: 10.1097/CMR.0000000000000446.

PMID:
29570169
8.
9.

Tumor-infiltrating lymphocytes predict cutaneous melanoma survival.

Fortes C, Mastroeni S, Mannooranparampil TJ, Passarelli F, Zappalà A, Annessi G, Marino C, Caggiati A, Russo N, Michelozzi P.

Melanoma Res. 2015 Aug;25(4):306-11. doi: 10.1097/CMR.0000000000000164.

PMID:
25933208
10.

Decreased tumor-infiltrating lymphocytes in nodular melanomas compared with matched superficial spreading melanomas.

Lin RL, Wang TJ, Joyce CJ, Mihm MC Jr, Murphy GF, Lian CG, Lin JY.

Melanoma Res. 2016 Oct;26(5):524-7. doi: 10.1097/CMR.0000000000000253.

PMID:
26974966
11.

Prognostic factors for metastasis in cutaneous melanoma.

Cherobin ACFP, Wainstein AJA, Colosimo EA, Goulart EMA, Bittencourt FV.

An Bras Dermatol. 2018 Jan-Feb;93(1):19-26. doi: 10.1590/abd1806-4841.20184779.

12.

Prognostic factors and epidemiological characteristics of cutaneous and mucosal head and neck melanoma.

Berzina A, Azarjana K, Cema I, Pjanova D, Rivosh A.

Stomatologija. 2011;13(2):49-54.

13.

Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study.

Thomas NE, Busam KJ, From L, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Venn A, Kanetsky PA, Groben PA, Hao H, Orlow I, Reiner AS, Luo L, Paine S, Ollila DW, Wilcox H, Begg CB, Berwick M.

J Clin Oncol. 2013 Nov 20;31(33):4252-9. doi: 10.1200/JCO.2013.51.3002. Epub 2013 Oct 14.

14.

Clinical and histopathologic predictors of survival in patients with malignant melanoma: a population-based study in Sweden.

Thörn M, Pontén F, Bergström R, Sparén P, Adami HO.

J Natl Cancer Inst. 1994 May 18;86(10):761-9.

PMID:
8169974
15.

Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.

Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N.

Cancer. 1996 Apr 1;77(7):1303-10.

16.

Solar elastosis and cutaneous melanoma: a site-specific analysis.

Kvaskoff M, Pandeya N, Green AC, Perry S, Baxter C, Davis MB, Mortimore R, Westacott L, Wood D, Triscott J, Williamson R, Whiteman DC.

Int J Cancer. 2015 Jun 15;136(12):2900-11. doi: 10.1002/ijc.29335. Epub 2014 Nov 26.

17.

Etiologic factors associated with p53 immunostaining in cutaneousmalignant melanoma.

Purdue MP, From L, Kahn HJ, Armstrong BK, Kricker A, Gallagher RP, McLaughlin JR, Klar NS, Marrett LD.

Int J Cancer. 2005 Nov 10;117(3):486-93.

18.

The prognostic significance of tumor-infiltrating lymphocytes for primary melanoma varies by sex.

Sinnamon AJ, Sharon CE, Song Y, Neuwirth MG, Elder DE, Xu X, Chu EY, Ming ME, Fraker DL, Gimotty PA, Karakousis GC.

J Am Acad Dermatol. 2018 Aug;79(2):245-251. doi: 10.1016/j.jaad.2018.02.066. Epub 2018 Mar 5.

PMID:
29518458
19.

The incidence and mortality of cutaneous melanoma in Southern Germany: trends by anatomic site and pathologic characteristics, 1976 to 2003.

Lasithiotakis KG, Leiter U, Gorkievicz R, Eigentler T, Breuninger H, Metzler G, Strobel W, Garbe C.

Cancer. 2006 Sep 15;107(6):1331-9.

20.

Association between tumor-infiltrating lymphocytes and sentinel lymph node positivity in thin melanoma.

Santos FMD, Silva FCD, Pedron J, Furian RD, Fortes C, Bonamigo RR.

An Bras Dermatol. 2019 Jan-Feb;94(1):47-51. doi: 10.1590/abd1806-4841.20197414.

Supplemental Content

Support Center